The FDA is reviewing GRAIL’s Premarket Approval application for the Galleri multi-cancer early detection test, which scans a single blood vial for signals from up to 50 cancer types.
In Plain English: The Clinical Takeaway
- Cell-Free DNA: The test analyzes chemical changes in cell-free DNA released by tumors into the bloodstream.
- Population Target: It is designed as a supplementary screening tool for asymptomatic adults aged 50 and older.
- Regulatory Milestone: GRAIL submitted its final Premarket Approval module in January 2026, putting formal FDA review on an accelerated track.
Regulatory Progress and the Path to Clinical Approval
A blood test capable of scanning for signals from up to 50 different cancer types in a single vial of blood is currently under formal FDA review. In January 2026, GRAIL, Inc. provided the final module of its Premarket Approval application to the FDA for the Galleri multi-cancer early detection test. This submission marks the most advanced regulatory step yet toward routine clinical use of what many oncologists consider a potentially transformative screening tool.
Should the FDA clear the test, it has the potential to transform the way cancer screening is approached for individuals in the United States aged 50 and older. According to GRAIL’s president, the test could eventually be covered by Medicare as early as 2028. The FDA previously designated Galleri as a Breakthrough Device in 2018. While it has been commercially available as a laboratory-developed test since 2021 with more than 475,000 tests sold, full FDA approval would clear the way for broader insurance coverage and formal reimbursement pathways.
Epidemiology and the Gap in Traditional Screening
As noted by GRAIL President Josh Ofman, MD, cancer continues to be the number one cause of death among U.S. adults past the age of 50. Most deadly cancers share a common challenge: they are discovered late, when treatment options are limited and clinical outcomes are significantly worse. Current cancer screening protocols are largely disease-specific, requiring separate appointments, distinct tests, and individual insurance coverage decisions for procedures like colonoscopy, mammography, and low-dose CT scans.
Crucially, many of the cancers most likely to prove fatal—including pancreatic, ovarian, and liver cancer—have no widely recommended screening test at all. Galleri is designed to address this vulnerability by detecting chemical changes in cell-free DNA that leak from tumors into the bloodstream. This mechanism of action allows the test to identify cancer signals from dozens of different tumor types from a single blood draw.
| Test Name | Manufacturer | Target Population | Key Clinical Data |
|---|---|---|---|
| Galleri | GRAIL, Inc. | Asymptomatic adults aged 50–77 | Evaluated in PATHFINDER 2 (25,490 participants) and NHS-Galleri (>140,000 participants). |
| SimpleScreen CRC | Freenome | Average-risk adults aged 45–85 | Detected ~8 in 10 colorectal cancers in a study of over 48,000 participants. |
| Shield | Guardant Health | Average-risk adults | FDA approved in 2024; free for patients with Medicare Part B. |
Clinical Trial Architecture and Evidence Base
The Premarket Approval submission is supported by data from two large-scale clinical investigations. The U.S.-based PATHFINDER 2 study enrolled 25,490 participants, while the NHS-Galleri trial enrolled more than 140,000 asymptomatic participants aged 50 to 77 across England. As a population screening evaluation of a multi-cancer early detection test, the NHS-Galleri trial remains the most extensive randomized controlled trial ever performed to measure clinical utility.
Clinical researchers involved in these studies have emphasized that the test is intended to complement, rather than replace, existing single-cancer screening modalities. Parallel developments in blood-based screening include FDA approvals for colorectal cancer detection tests, such as Freenome’s SimpleScreen CRC and Guardant Health’s Shield, highlighting a broader regulatory shift toward non-invasive diagnostics.
Contraindications & When to Consult a Doctor
Multi-cancer early detection blood tests are specifically engineered for asymptomatic adults who have no clinical suspicion of active cancer. They are not diagnostic tools for individuals currently presenting with unexplained weight loss, localized pain, or other constitutional symptoms suggestive of malignancy. Patients who receive a positive signal from a screening blood test must undergo confirmatory diagnostic evaluations, such as imaging or biopsies, to verify the presence of disease. Anyone experiencing persistent, unexplained physical symptoms should consult a primary care physician immediately rather than waiting for routine screening intervals.
The Future Landscape of Population Screening
Rural communities in the South, the Appalachian region, and parts of the Midwest stand to benefit from a blood test ordered during a routine primary care visit.
References
- Medical Daily. “One Blood Test Could Detect 50 Cancers at Once — the FDA Decision That Could Change Screening Forever.” Published 2026.
- The Independent. “New blood test to detect colon cancer clears FDA approval.” Published 2026.
- PATHFINDER 2 Study Data and NHS-Galleri Trial Registries. ClinicalTrials.gov.
